Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of YHP2205 and YHR2401 (Edoxaban) in Healthy Subjects
NCT06359626Phase 1Completed
- Sponsor
- Yuhan
- Start
- Jun 2024
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of edoxaban in Atrial fibrillation (AFib) and venous thromboembolism (VTE) (2 arms), sponsored by Yuhan. Primary endpoints: Area under the plasma drug concentration-time curve from time 0 to time t and Maximum plasma concentration. Started Jun 2024; status: completed.
02
Drugs
edoxaban
03
Conditions
Atrial fibrillation (AFib)venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT06359626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06359626.